– Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – Next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, TNG456, planned to enter the clinic in 1H 2025 – – Strong cash position of $293 million as of September 30, 2024, with cash runway into 3Q 2026 to prioritize resourcing of TNG462 and TNG456 clinical trials – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discoveri

– TNG462 demonstrated durable clinical activity across multiple tumor types, including non-small cell lung cancer (NSCLC) and pancreatic cancer, in ongoing phase 1/2 clinical trial, moving into full development – – Multiple TNG462 combination studies planned in 1H 2025 – – Clinical collaboration established with Revolution Medicines to evaluate TNG462 in combination with RAS(ON) multi- and G12D-selective inhibitors – – TNG456, a next-generation brain penetrant MTA-cooperative PRMT5 inhibitor with enhanced potency and MTAP-deleted-selectivity, entering phase 1/2 clinical trial 1H 2025 to be evaluated both as a monotherapy and in combination with CDK4/6 inhibitor abemaciclib – – TNG908 en

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in September. 2024 Wells Fargo Healthcare Conference Date: Wednesday, September 4, 2024 Time: 12:45 PM ET Location: Boston, MA 2024 Cantor Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 9:10 AM ET Location: New York, NY A live webcast of the presentations will be available under the "Events & Presentations" tab on the "In

– Dose expansion ongoing in TNG908 and TNG462 phase 1/2 clinical trials; comprehensive clinical data update for the PRMT5 program expected in 2H 2024 – – Patient enrollment is ongoing in TNG260 phase 1/2 clinical trial – – Strong cash position of $322 million as of June 30, 2024; cash runway into 2027 expected to fund clinical programs through proof-of-concept – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the second quarter ended June 30, 2024, and provided business highlights. "In the second quarter, we continued to advance

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET. A live webcast of the presentation will be available under the "Events & Presentations" tab on the "Investors" page on the Company's website on the day of the event. A replay of the webcast will be archived on the Company's website for 90 days following the presentation. About Tango Therapeutic

STOCKHOLM, May 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that Medivir's licensee, Tango Therapeutics (NASDAQ:TNGX, Tango))), has announced that the phase 1/2 clinical trial of TNG348, a novel USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts.  TNG348 is a novel USP1 (ubiquitin-specific protease 1) inhibitor, for the treatment of BRCA1/2-mutant and other homologous recombination deficiency (HRD)+ cancers, and has been developed by Tango from the preclinical USP1 program licensed from Medivir in 2020. A

– The phase 1/2 clinical trial of TNG348, a USP1 inhibitor, is being terminated due to toxicity observed in the initial study cohorts – – Cash runway extended into 2027, PRMT5 and CoREST clinical programs remain on track – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program. "Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced b

– Dose expansion initiated in TNG908 phase 1/2 clinical trial – – Dose expansion expected to initiate in TNG462 phase 1/2 clinical trial in 2Q 2024 – – Clinical data expected in 2H 2024 from PRMT5 program – – Dose escalation ongoing in TNG260 and TNG348 clinical-stage precision oncology programs – – Strong cash position of $344 million as of March 31, 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 3

Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to R

– Dose escalation ongoing in four clinical-stage precision oncology programs; TNG908 phase 1/2 clinical data expected in 2024 – – First patient dosed in phase 1/2 clinical trial of TNG348 in patients with BRCA1/2-mutant and other HRD+ cancers – – FDA Orphan Drug Designation granted for TNG462 for the treatment of soft tissue sarcomas – – Strong cash position of $337 million as of December 31, 2023, combined with $42 million in proceeds from ATM in January 2024; cash runway into late 2026 expected to fund all clinical programs through proof-of-concept – Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next gene

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

3 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed

– Fast Track Designation granted to TNG462, next-generation MTA-Cooperative PRMT5 inhibitor – – Adam Crystal, M.D., Ph.D. appointed President of Research and Development – BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2022, and provided business highlights. "2022 was an important year for Tango, as we made critical strides in advancing our programs. We advanced our pipeline of precision oncology programs with the addition of three synthe

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development. In this executive leadership role, Dr. Crystal will oversee all phases of preclinical research, drug discovery and clinical development. Alan Huang, Ph.D., Chief Scientific Officer, and Ron Weitzman, M.D., Ph.D., Chief Medical Officer, will continue to lead the research and clinical development functions, respectively, as members of Dr. Crystal's team. "Adam is joining at a pivot

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA'))), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. "Katia has had a major impact on HOOKIPA's clinical development strategy and execution in immuno-oncology therapeutics and vaccines since she joined the Company in 2021. She will be leading the progression of our clinical programs to the next level, specifically our own programs in head and n

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France –         – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers –            – TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers – – Aaron Weitzman, M.D., F.A.C.P., appointed Chief Medical Officer – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial res

CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced two recent senior management appointments: Marc Rudoltz, M.D., as Chief Medical Officer, and Doug Barry, J.D., as General Counsel. "Marc‘s deep experience in oncology-clinical development, and particular focus on targeted therapy, will be of great benefit as Tango advances into the clinic in the first half of 2022 with TNG908, our MTA-cooperative PRMT5 inhibitor," said Barbara Weber, M.D., president and Chief Executive Officer of Tango Therapeutics. "I'm equally excited

10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)

8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

144 - Tango Therapeutics, Inc. (0001819133) (Subject)

10-Q - Tango Therapeutics, Inc. (0001819133) (Filer)

8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight

Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00

B. Riley Securities initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $16.00

H.C. Wainwright upgraded Tango Therapeutics from Neutral to Buy and set a new price target of $10.00

SVB Leerink initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $25.00

Wedbush initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $12.00

Wedbush initiated coverage of Tango Therapeutics with a rating of Outperform and set a new price target of $20.00

Guggenheim initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $16.00

Goldman Sachs initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $17.00

SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13G/A - Tango Therapeutics, Inc. (0001819133) (Subject)